Product Data Analysis Intern

Accuray appoints Paul Miele as Senior Vice President and Chief Commercial Officer. April 6, 2026 at 9:00 AM EDT MADISON, Wis., April 6, 2026 /PRNewswire/ - Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio. "Paul brings deep global commercial leadership experience and a strong track record of driving transformation and sales growth in complex medical technology businesses," said Steve La Neve, President and Chief Executive Officer of Accuray. "His background in rebuilding commercial operating models, accelerating capital equipment and services sales, and unlocking recurring revenue opportunities will be instrumental as we continue to strengthen our commercial performance and position Accuray for long-term value creation." Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as Business Unit Leader and General Manager for the MONARCH(TM) robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical. As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence. "Accuray has a strong foundation of innovation, a large installed base, a group of dedicated distribution partners, and a meaningful opportunity to further strengthen its commercial impact worldwide," said Paul Miele. "Most importantly, Accuray's products are vital to treating cancer patients in 70+ countries around the world. I'm excited to join the team and help drive growth in systems and services sales, with a particular focus on marketing and selling value-added solutions to our customers, on commercial execution, and on carrying out Accuray's mission for the benefit of countless customers and patients." About Accuray Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. Accuray Incorporated invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases - while making commonly treatable cases even easier - to meet the full spectrum of patient needs. Accuray Incorporated is dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as Accuray Incorporated partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, expectations regarding the Company's new Chief Commercial Officer and ability to strengthen commercial performance. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 17, 2026, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. Media Contact Steve Monroe Vice President, Financial Planning & Analysis - Accuray [email protected] Investor Contact Aman Patel, CFA Investor Relations, ICR-Westwicke [email protected] SOURCE Accuray Incorporated

Accuray (NASDAQ: ARAY) sets separation terms for chief commercial officer. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Accuray Incorporated entered into a separation agreement with Senior Vice President and Chief Commercial Officer Sandeep Chalke on March 13, 2026, ahead of his previously disclosed departure effective March 31, 2026. The agreement grants vesting of equity awards scheduled to vest on May 31, 2026, with all later equity forfeited. Mr. Chalke will receive a lump-sum cash payment of $459,000, equal to 12 months of base salary, plus a pro-rated fiscal 2026 bonus paid on the same schedule as other executives. These benefits replace any prior severance or noncompetition payments, and the agreement, which includes a general release of claims, becomes effective after a seven-business-day revocation period. 03/19/2026 - 04:01 PM Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. As previously disclosed, Sandeep Chalke, the Senior Vice President, Chief Commercial Officer of Accuray Incorporated (the "Company"), will depart from the company effective March 31, 2026. In connection with Mr. Chalke's departure, on March 13, 2026, the Company entered into a separation agreement and general release (the "Separation Agreement") with Mr. Chalke. The Separation Agreement provides for (i) the vesting of Mr. Chalke's equity grants that were due to vest on May 31, 2026 under the Company's Equity Incentive Plan, with all equity due to vest after that date forfeited, (ii) a lump sum payment of $459,000, equal to twelve (12) months of Mr. Chalke's annual base salary; and (iii) a pro-rated portion of the bonus Mr. Chalke would have received for the Company's fiscal year 2026 under the Company's bonus plan, payable at the same time as bonuses are paid to other Company executives. These benefits are provided in lieu of any other severance payments or noncompetition consideration under prior agreements, and the Separation Agreement, which includes a general release of claims, becomes effective upon expiration of a seven-business-day revocation period following execution. The foregoing summary of the terms of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is filed as an Exhibit 10.1 hereto. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Faq. What executive change does Accuray (ARAY) describe in this 8-K? Accuray details the planned departure of Sandeep Chalke, its Senior Vice President and Chief Commercial Officer, effective March 31, 2026. The filing focuses on the terms of his separation agreement, including equity vesting, cash severance, and a pro-rated fiscal 2026 bonus. What cash severance will Sandeep Chalke receive from Accuray (ARAY)? Under the separation agreement, Sandeep Chalke will receive a lump-sum cash payment of $459,000. This amount equals 12 months of his annual base salary and is provided in lieu of any other severance or noncompetition consideration under his prior agreements with the company. How are Accuray (ARAY) equity awards treated in Sandeep Chalke's separation? Accuray will allow Mr. Chalke's equity grants scheduled to vest on May 31, 2026 to continue vesting. Any equity awards that were due to vest after that date will be forfeited, limiting ongoing equity benefits to the near-term vesting tranche only. Will Sandeep Chalke receive a bonus from Accuray (ARAY) after his departure? Yes. The agreement provides a pro-rated bonus for Accuray's fiscal year 2026. That bonus amount will be calculated under the company's bonus plan and paid at the same time as bonuses are paid to other Accuray executives for that fiscal year. When does Sandeep Chalke's separation agreement with Accuray (ARAY) become effective? The separation agreement, signed on March 13, 2026, becomes effective after a seven-business-day revocation period following execution. It also includes a general release of claims by Mr. Chalke in exchange for the severance and equity benefits described. What does Accuray (ARAY) file as an exhibit related to this executive departure? Accuray files the full Separation Agreement and General Release with Sandeep Chalke as Exhibit 10.1. This exhibit contains the complete legal terms and conditions governing his departure, compensation, equity treatment, and release of claims against the company. Filing exhibits & attachments. 5 documents Agreements & contracts.

PRECISE partners with Accuray for linear accelerator vault renovation at James A. Haley Veterans' Hospital, Tampa, FL. PRECISE is pleased to announce a partnership with medical equipment manufacturer Accuray on the design-build renovation of a linear accelerator vault and control room at James A. Haley Veterans' Hospital in Tampa, Florida. The project will fully renovate an existing radiation therapy vault to accommodate an Accuray Radixact Treatment Delivery System. The Accuray Radixact system delivers highly precise radiation therapy by combining integrated imaging, real-time motion synchronization, and continuous 360-degree treatment delivery to accurately target tumors while minimizing exposure to surrounding healthy tissue. This technology helps clinicians improve patient outcomes and reduce side effects. Construction is scheduled to begin in November 2025. Since 2010, PRECISE has partnered with Accuray as a trusted design-build collaborator, successfully completing 22 projects featuring Radixact and CyberKnife treatment systems.